Lumasiran for high oxalate patients on hemodialysis
Part of Heart & circulation clinical trials.
This trial tests a drug called Lumasiran to lower oxalate levels in patients on hemodialysis (a type of kidney dialysis). It may help reduce complications from high oxalate, which can damage organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have been on hemodialysis (three times a week) for at least 2 months.
- You need a permanent dialysis access (like a fistula or graft).
- Your average blood oxalate level must be 20 μmol/L or higher.
- You cannot have primary hyperoxaluria (a genetic cause of high oxalate).
- No major medication or diet changes in the last 2 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients with primary hyperoxaluria type 1 who are being treated with Lumasiran. It aims to understand how well the treatment works over time.
This trial compares two ways of giving Lumason (an ultrasound contrast agent) to improve images of the left ventricle in people whose initial heart ultrasound was unclear. It may help those with a 'suboptimal' view of the heart's pumping chamber.
This trial tests an experimental drug called YOLT-203 for people with type 1 primary hyperoxaluria (PH1), a rare condition that causes high oxalate levels and can damage the kidneys. It aims to see if YOLT-203 can safely help manage the disease.
This Phase 2 study tests a medicine called DCR-PHXC to lower body oxalate levels in people with PH1 who have advanced kidney failure. By lowering oxalate, the treatment may reduce harm from oxalate buildup and help researchers understand safety and effectiveness.
This trial tests a new drug called HLX79 (a human sialidase fusion protein) combined with rituximab, compared to a placebo, for people with active membranous nephropathy (a kidney disease). It aims to see if this combination can reduce protein in the urine and improve kidney function.
This trial tests a new oral medication, coated aldehyde oxystarch, for people on dialysis. It aims to lower certain waste products in the blood that are hard to remove with standard dialysis, which may help reduce long-term complications.
Hear when a new Haemodialysis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.